The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a gain of 0.60%.However, over the last six months, we can see a weaker performance of 80.36%. Over the last 30 days, the price of CERE has fallen by 0.77%. And in the last five days, it has surged by 1.39%.
Cerevel Therapeutics Holdings Inc’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $43.59 on 02/15/24 and a low of $19.59 for the same time frame on 10/04/23.
52-week price history of CERE Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cerevel Therapeutics Holdings Inc’s current trading price is -2.14% away from its 52-week high, while its distance from the 52-week low is 117.74%. The stock’s price range during this period has varied between$19.59 and $43.59. The Cerevel Therapeutics Holdings Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.95 million for the day, a figure considerably lower than their average daily volume of 1.39 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cerevel Therapeutics Holdings Inc (CERE) has experienced a quarterly rise of 2.02% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 7.76B and boasts a workforce of 334 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 41.98, with a change in price of +1.55. Similarly, Cerevel Therapeutics Holdings Inc recorded 1,837,742 in trading volume during the last 100 days, posting a change of +3.77%.
CERE’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CERE stands at 0.71. Similarly, the long-term debt-to-equity ratio is also 0.71.
CERE Stock Stochastic Average
As of today, Cerevel Therapeutics Holdings Inc’s raw stochastic average for the last 50 days stands at 90.99%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 88.20%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 88.78% and 90.85%, respectively.
